세계의 녹농균 감염증 치료제 시장 : 시장 규모 분석(브랜드별, 용도별, 지역별) 및 예측(2022-2032년)

Global Pseudomonas Aeruginosa Infection Treatment Market is valued at approximately USD 11.3 billion in 2023 and is projected to grow at a steady compound annual growth rate (CAGR) of 2.80% during the forecast period from 2024 to 2032. The increasing prevalence of drug-resistant bacterial infections has positioned Pseudomonas aeruginosa-an opportunistic pathogen notorious for its resilience and biofilm-forming capabilities-at the forefront of global health concerns. It is particularly rampant in hospital settings, afflicting immunocompromised patients through infections such as ventilator-associated pneumonia, urinary tract infections, and bloodstream infections. The treatment landscape has grown increasingly sophisticated, driven by a pipeline of targeted antimicrobial therapies and evolving guidelines for antimicrobial stewardship.

As healthcare systems grapple with the surge of multidrug-resistant strains, the demand for effective Pseudomonas aeruginosa infection treatments is gaining traction. Brands like Tradjenta, Nesina, and Galvus, although primarily associated with other therapeutic domains, represent the level of pharmaceutical innovation that the infectious disease segment is striving to replicate. Novel B-lactam/B-lactamase inhibitor combinations, liposomal delivery systems, and inhalation-based antibiotics are reshaping treatment protocols. This shift is fueled by ongoing research in genomics, pathogen profiling, and targeted drug development to overcome intrinsic resistance mechanisms. Despite these advances, challenges such as limited drug penetration at infection sites and the rapid emergence of resistance to even last-line antibiotics continue to hinder optimal treatment outcomes.

Government agencies, pharmaceutical innovators, and global health alliances are actively forging partnerships to strengthen the development and accessibility of Pseudomonas-targeted therapies. Funding initiatives from entities such as the Global Antibiotic Research and Development Partnership (GARDP) and the Biomedical Advanced Research and Development Authority (BARDA) have catalyzed R&D efforts aimed at high-risk bacterial pathogens. Further, increasing hospital infection surveillance and implementation of precision diagnostics are expected to streamline therapy choices and boost adoption of advanced treatment regimens, while enabling hospitals to reduce patient recovery time and improve outcomes.

Regionally, North America dominates the global Pseudomonas aeruginosa treatment market, benefiting from an advanced regulatory landscape, a concentration of biotech hubs, and robust reimbursement structures. Europe follows closely, supported by increasing antibiotic stewardship programs and investments in clinical research. The Asia Pacific region is poised for the fastest growth, propelled by escalating infection rates, healthcare infrastructure modernization, and rising awareness across populous countries like India and China. Meanwhile, Latin America and the Middle East & Africa regions are expanding steadily due to growing government efforts and international aid focused on infectious disease containment and hospital care enhancement.

Major market player included in this report are:

• AstraZeneca PLC
• Eli Lilly and Company
• Novartis AG
• Jiangsu Hengrui Pharmaceuticals Co., Ltd.
• Sanofi S.A.
• Merck & Co., Inc.
• Glenmark Pharmaceuticals Ltd.
• Wockhardt Ltd.
• Hanmi Pharmaceuticals
• LG Chem
• Takeda Pharmaceutical Company Limited
• Boehringer Ingelheim International GmbH
• Teijin Pharma Ltd.
• Sun Pharmaceutical Industries Ltd.
• Alkem Laboratories Ltd.

The detailed segments and sub-segment of the market are explained below:

By Brand

• Tradjenta
• Nesina
• Onglyza
• Januvia
• Vipidia
• Galvus

By Application

• Type 2 Diabetes Mellitus
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1. Global Pseudomonas Aeruginosa Infection Treatment Market Executive Summary

• 1.1. Global Pseudomonas Aeruginosa Infection Treatment Market Size & Forecast (2022-2032)
• 1.2. Regional Summary
• 1.3. Segmental Summary
  • 1.3.1. By Brand
  • 1.3.2. By Application
• 1.4. Key Trends
• 1.5. Recession Impact
• 1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Pseudomonas Aeruginosa Infection Treatment Market Definition and Research Assumptions

• 2.1. Research Objective
• 2.2. Market Definition
• 2.3. Research Assumptions
  • 2.3.1. Inclusion & Exclusion
  • 2.3.2. Limitations
  • 2.3.3. Supply Side Analysis
    • 2.3.3.1. Availability
    • 2.3.3.2. Infrastructure
    • 2.3.3.3. Regulatory Environment
    • 2.3.3.4. Market Competition
    • 2.3.3.5. Economic Viability (Provider's Perspective)
  • 2.3.4. Demand Side Analysis
    • 2.3.4.1. Regulatory Frameworks
    • 2.3.4.2. Technological Advancements
    • 2.3.4.3. Environmental Considerations
    • 2.3.4.4. Stakeholder Awareness & Acceptance
• 2.4. Estimation Methodology
• 2.5. Years Considered for the Study
• 2.6. Currency Conversion Rates

Chapter 3. Global Pseudomonas Aeruginosa Infection Treatment Market Dynamics

• 3.1. Market Drivers
  • 3.1.1. Escalating Drug-Resistant P. aeruginosa Incidence
  • 3.1.2. Growing Adoption of Advanced Antimicrobial Therapies
  • 3.1.3. Strengthening Hospital Infection Control Protocols
• 3.2. Market Challenges
  • 3.2.1. Rapid Emergence of Last-Line Antibiotic Resistance
  • 3.2.2. Limited Penetration of Novel Therapies in Emerging Markets
  • 3.2.3. High R&D Costs and Regulatory Barriers
• 3.3. Market Opportunities
  • 3.3.1. Expansion of Precision Diagnostics and Rapid Molecular Tests
  • 3.3.2. Partnerships for Antibiotic Development (e.g., GARDP, BARDA)
  • 3.3.3. Growth in Inhalation and Liposomal Delivery Formulations

Chapter 4. Global Pseudomonas Aeruginosa Infection Treatment Market Industry Analysis

• 4.1. Porter's Five Forces Model
  • 4.1.1. Bargaining Power of Suppliers
  • 4.1.2. Bargaining Power of Buyers
  • 4.1.3. Threat of New Entrants
  • 4.1.4. Threat of Substitutes
  • 4.1.5. Competitive Rivalry
  • 4.1.6. Futuristic Approach to Porter's Five Forces
  • 4.1.7. Impact Analysis
• 4.2. PESTEL Analysis
  • 4.2.1. Political
  • 4.2.2. Economical
  • 4.2.3. Social
  • 4.2.4. Technological
  • 4.2.5. Environmental
  • 4.2.6. Legal
• 4.3. Top Investment Opportunity
• 4.4. Top Winning Strategies
• 4.5. Disruptive Trends
• 4.6. Industry Expert Perspectives
• 4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Pseudomonas Aeruginosa Infection Treatment Market Size & Forecasts by Brand 2022-2032

• 5.1. Segment Dashboard
• 5.2. Revenue Trend Analysis by Brand, 2022 & 2032 (USD Billion)
  • 5.2.1. Tradjenta
  • 5.2.2. Nesina
  • 5.2.3. Onglyza
  • 5.2.4. Januvia
  • 5.2.5. Vipidia
  • 5.2.6. Galvus

Chapter 6. Global Pseudomonas Aeruginosa Infection Treatment Market Size & Forecasts by Application 2022-2032

• 6.1. Segment Dashboard
• 6.2. Revenue Trend Analysis by Application, 2022 & 2032 (USD Billion)
  • 6.2.1. Type 2 Diabetes Mellitus
  • 6.2.2. Others

Chapter 7. Global Pseudomonas Aeruginosa Infection Treatment Market Size & Forecasts by Region 2022-2032

• 7.1. North America Market
  • 7.1.1. U.S. Market
    • 7.1.1.1. Brand breakdown, 2022-2032
    • 7.1.1.2. Application breakdown, 2022-2032
  • 7.1.2. Canada Market
• 7.2. Europe Market
  • 7.2.1. UK Market
  • 7.2.2. Germany Market
  • 7.2.3. France Market
  • 7.2.4. Spain Market
  • 7.2.5. Italy Market
  • 7.2.6. Rest of Europe Market
• 7.3. Asia Pacific Market
  • 7.3.1. China Market
  • 7.3.2. India Market
  • 7.3.3. Japan Market
  • 7.3.4. Australia Market
  • 7.3.5. South Korea Market
  • 7.3.6. Rest of APAC Market
• 7.4. Latin America Market
  • 7.4.1. Brazil Market
  • 7.4.2. Mexico Market
  • 7.4.3. Rest of Latin America Market
• 7.5. Middle East & Africa Market
  • 7.5.1. Saudi Arabia Market
  • 7.5.2. South Africa Market
  • 7.5.3. Rest of MEA Market

Chapter 8. Competitive Intelligence

• 8.1. Key Company SWOT Analysis
  • 8.1.1. AstraZeneca PLC
  • 8.1.2. Eli Lilly and Company
  • 8.1.3. Novartis AG
• 8.2. Top Market Strategies
• 8.3. Company Profiles
  • 8.3.1. AstraZeneca PLC
    • 8.3.1.1. Key Information
    • 8.3.1.2. Overview
    • 8.3.1.3. Financial (Subject to Data Availability)
    • 8.3.1.4. Product Summary
    • 8.3.1.5. Market Strategies
  • 8.3.2. Eli Lilly and Company
  • 8.3.3. Novartis AG
  • 8.3.4. Jiangsu Hengrui Pharmaceuticals Co., Ltd.
  • 8.3.5. Sanofi S.A.
  • 8.3.6. Merck & Co., Inc.
  • 8.3.7. Glenmark Pharmaceuticals Ltd.
  • 8.3.8. Wockhardt Ltd.
  • 8.3.9. Hanmi Pharmaceuticals
  • 8.3.10. LG Chem
  • 8.3.11. Takeda Pharmaceutical Company Limited
  • 8.3.12. Boehringer Ingelheim International GmbH
  • 8.3.13. Teijin Pharma Ltd.
  • 8.3.14. Sun Pharmaceutical Industries Ltd.
  • 8.3.15. Alkem Laboratories Ltd.

Chapter 9. Research Process

• 9.1. Research Process
  • 9.1.1. Data Mining
  • 9.1.2. Analysis
  • 9.1.3. Market Estimation
  • 9.1.4. Validation
  • 9.1.5. Publishing
• 9.2. Research Attributes